Business Wire

Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration

Share

Croma-Pharma (Croma) today announced the addition of juvenus to its product portfolio. It is an injectable, elastic, colourless and reabsorbable gel, based on polymerized polynucleotides (PDRN)1,2 of natural origin, which hydrates the skin and restores tissue elasticity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210913005466/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Croma-Pharma Presents juvenus, a New Polynucleotide Based Injectable for Skin Hydration and Tissue Elasticity Restoration (Photo: Business Wire)

juvenus is produced by a European certified manufacturer and distributed by Croma. In a first phase Croma will market the product within its network of affiliated sales companies (AT, FR, DE, NL, PL, PT, RO, ES, CH, UK, IT), followed by other European markets via independent distribution partners.3

Innovative mode of action to fight signs of skin aging
Thanks to its biochemical properties, juvenus improves skin elasticity and is effective against various signs of aging, such as wrinkles, loss of skin firmness or skin tone. The elastic and injectable gel is based on polymerized polynucleotides (PDRN), showing several positive effects on the skin:

- Antioxidative effect: The enzyme-related degradation of polynucleotide molecules can lead to an amplification of protective activities against free radicals. 4

- Moisturization: The hydrophilic and polyanionic structure enables PDRN to bind water molecules, resulting in an intensive moisturization of the tissue.

- Creation of an optimal environment for fibroblast growth: Extensive moisturization and the antioxidative activity contribute to the creation of an optimal physiological environment for the growth of the fibroblasts favoring the restoration of the tissue elasticity​.5

Two concentrations for different types of skin blemishes
juvenus is available in two concentrations and suitable for all skin types and age groups:

- juvenus 2%, medium: slightly deeper wrinkles, such as superficial perioral wrinkles, cheek wrinkles, medium scars

- juvenus 2,5%, strong: medium-deep wrinkles and larger areas of the body, such as neck, back of the hands, abdomen, cleavage, thighs and glutes, nasogenien wrinkles, deep/large scars

Broad range of indications for facial and body treatments with a proven safety profile
The application range of juvenus is extensive and stretches from the treatment of slightly deeper facial wrinkles to the treatment of larger areas of the body.

juvenus shows a proven safety profile due to the PDRN extraction and purification at high temperature – a procedure that allows to recover an over 95% pure active substance with inactivated proteins and peptides. The latter guarantees the safety of the product and the lack of immunological side effects.

"Croma always strives to bring exceptional products to the market that meet the growing demands of our customers. With juvenus, we can offer a new and safe injectable with an innovative mode of action that targets the signs of skin aging," comments Managing Director Andreas Prinz.

About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.

The medical practitioner confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use. For risks and adverse events associated with the use of the product consult the instructions of use.


1 Müller Esterl, Biochemie. 1. Auflage 2004, Elsevier

2 Squadrito F, Bitto A, Irrera N, Pizzino G, Pallio G, Minutoli L and Altavilla D (2017) Pharmacological Activity and Clinical Use of PDRN. Front. Pharmacol. 8:224. doi: 10.3389/fphar.2017.00224

3 available with CE 0373

4 Cavallini M, Papagni M. Long chain polynucleotides gel and skin biorevitalization. Int J Plast Dermatol 2007; 3: 27-32.

5 Pak CS, Lee J, Lee H, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow’s feet: a new concept of regenerative filler. J Korean Med Sci 2014: 29: 201– 209.

PRJ0821

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at

CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Interactive Brokers Launches Ask IBKR: AI Tool Delivers Instant Portfolio Answers15.10.2025 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Ask IBKR, an AI-powered tool that delivers instant portfolio insights through natural language queries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015991473/en/ “With Ask IBKR, we’re introducing a natural language-based way for investors to interact with their portfolio data,” said Milan Galik, Chief Executive Officer at Interactive Brokers. “Instead of navigating across screens, clients can simply ask, ‘What sector am I underweight compared to the S&P 500?’ and get an instant, visualized answer.” Categories of queries include: Portfolio Metrics: Compare performance against benchmarks, identify valuation changes over time, and highlight periods of outperformance or underperformance Allocation Analysis: Analyze sector exposure, compare returns across asset classes, and assess performance by instrument type Holdings

Multiply Group Announces Plans to Acquire 2PointZero and Ghitha Holding via Share Swap15.10.2025 16:36:00 EEST | Press release

Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today announced that its Board has approved a proposal to acquire 2PointZero and Ghitha Holding through a share swap transaction. Under the proposed terms, Multiply Group would offer shares to acquire 2PointZero and Ghitha Holding, followed by the issuance of new shares to complete the transaction. The transaction is currently under review and remains subject to shareholder and regulatory approvals. 2PointZero is a transformational investment company with scalable assets in energy, mining, and financial services, serving as an AI enabler and energy transition accelerator driving a smarter, more sustainable future. Ghitha Holding is a leading conglomerate spanning agriculture, food production, and distribution operations that play a vital role in food security. Together, these businesses represent complementary strengths across the Energy and Consumer sectors,

Svante Hails Nobel Prize in Chemistry, Validating Metal-Organic Framework Technology is Critical for Commercial Carbon Capture15.10.2025 16:30:00 EEST | Press release

Svante, a leader in solid sorbent-based carbon capture and removal filter technology, celebrated the announcement of the 2025 Nobel Prize in Chemistry last week, which honored scientists Susumu Kitagawa, Richard Robson and Omar Yaghi for their groundbreaking work in the metal-organic framework (MOF) field. ​The Royal Swedish Academy of Sciences awarded the prize for the development of MOFs, citing their "enormous potential" and unique molecular architecture that creates spacious, porous materials capable of capturing and storing specific substances, including carbon dioxide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015855374/en/ Svante scientist holding a jar of metal-organic framework (MOF), a relatively new class of nanomaterials for carbon capture mentioned in the Nobel Prize for Chemistry ​Richard Laliberté, Svante’s COO and President of Svante OEM&D, stated, “The Nobel Committee’s recognition of the very class

New NIQ Report: Quality, Convenience, and Hygiene to Drive Growth in Home Appliances Market in 202615.10.2025 16:00:00 EEST | Press release

NielsenIQ (NYSE: NIQ) today released its Home Appliances Outlook 2026: What consumers want report, which reveals the macro forces that will shape the Home Appliances industry in 2026 and the product innovation most likely to drive growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015103990/en/ NIQ projects a 2% year-over-year sales growth between 2024 and 2025 for global Consumer Tech and Durable Goods (T&D), with household appliances playing a significant part in that growth. Global sales of T&D products overall grew 4.6% in the first half of 2025 compared with the same period in 2024, with consumers spending more per item in all sectors except Major Domestic Appliances (MDA). Consumers remain cautious in their spending but are willing to pay for appliances that offer smart convenience, multifunctionality, energy efficiency, or health and hygiene benefits. New Market Realities Reshape the Home Appliances Landscape C

Impartner Launches HyperscalerGTM, the First Unified Partner-to-Marketplace Automation15.10.2025 16:00:00 EEST | Press release

Impartner, the global leader in partner management and partner marketing automation, today announced the launch of HyperscalerGTM, a disruptive new solution that unifies the entire partner-to-cloud-marketplace journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015648514/en/ The launch of HyperscalerGTM represents the most significant advancement in partner automation in a decade, introducing a disruptive solution that unifies the entire partner-to-cloud-marketplace journey. For the first time ever, vendors can enable partners to register deals, collaborate with hyperscaler field teams, and transact directly in cloud marketplaces all from within a single, automated workflow. The result is a faster, simpler path from partner registration to closed marketplace revenue. “HyperscalerGTM is the most significant advancement in partner automation in a decade,” said Joe Wang, CEO of Impartner. "By integrating the deal registr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye